by ebensoncox | Jan 4, 2023 | Blog
STATinMED at ASH 2022 64th Annual ASH Meeting & Exposition: Dec 10-13, 2022, New Orleans, LA Presentations Oral Presentation: National view of prevalent and newly-diagnosed patients with multiple myeloma in 2021: A retrospective analysis of national...
by evivier@statinmed.com | Dec 20, 2022 | Blog
Our Vice President, Real-World Evidence (RWE) shares her perspective about HEOR, RWD, evidence generation, and more. (First in a 2-part series) What is the current landscape for pharmaceutical and biotechnology products? It is an exciting time. I’ve spent 30 years in...
by ebensoncox | Oct 18, 2022 | Blog
Access robust business intelligence from a reliable team of analysts who understand your goals Get timely real-world data insights to make business decisions quickly Contact us about RWD Insights Direct STATinMED RWD Custom Registry Actionable, research-ready data...
by evivier@statinmed.com | Oct 5, 2022 | Blog
Lowering prescription drug costs and health care costs are among the goals of the Inflation Reduction Act. While changes will not take effect until 2025, what can the biopharmaceutical industry expect? Keshia Maughn, Senior Principal, Strategic Advisory Services at...
by evivier@statinmed.com | Aug 30, 2022 | Blog
More from our VP of RWE, Maxine Fisher, PhD What is the team’s approach with RWD to generate evidence and demonstrate value? One thing that is very motivating about working at STATinMED is our collaborative and consultative approach to generating evidence. RWD...
by ebensoncox | Aug 15, 2022 | Blog
Introducing… Timely resource based on index dates with ability to track time-varying events Patient-centric insights about treatment journey De-identified, tokenized, HIPAA-compliant Views You Can Use Collect the variables to...
